Martha A. Cady

Martha A. Cady

Auto-generated profile, based on publicly available information

Martha A. Cady

Department of Radiation Oncology, University of California, San Francisco , San Francisco, California

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2024 in Cancer Discovery
Verified
Journal Article
Closed access
ACAbrar Choudhury
Abrar Choudhury
MCMartha A. Cady
Martha A. Cady
CLCalixto-Hope G. Lucas
Calixto-Hope G. Lucas
HNHINDA NAJEM
HINDA NAJEM
JPJoanna J. Phillips
Joanna J. Phillips
DRDavid R. Raleigh
David R. Raleigh
Meningiomas are the most common primary intracranial tumors. Treatments for patients with meningiomas are limited to surgery and radiotherapy, and systemic therapies remain ineffective or experimental. Resistance to radiotherapy is common in high-grade meningiomas and the cell types and signaling mechanisms that drive meningioma tumorigenesis and resistance to radiotherapy are incompletely understood. Here, we report that NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy and find that perivascular NOTCH3+ stem cells are conserved across meningiomas from humans, dogs, and mice. Integrating single-cell transcriptomics with lineage tracing and imaging approaches in genetically engineered mouse models and xenografts, we show NOTCH3 drives tumor-initiating capacity, cell proliferation, angiogenesis, and resistance to radiotherapy to increase meningioma growth and reduce survival. To translate these findings to patients, we show that an antibody stabilizing the extracellular negative regulatory region of NOTCH3 blocks meningioma tumorigenesis and sensitizes meningiomas to radiotherapy, reducing tumor growth and improving survival. Significance: There are no effective systemic therapies to treat meningiomas, and meningioma stem cells are poorly understood. Here, we report perivascular NOTCH3+ stem cells to drive meningioma tumorigenesis and resistance to radiotherapy. Our results identify a conserved mechanism and a therapeutic vulnerability to treat meningiomas that are resistant to standard interventions.

21 May 2026 in Neuro-Oncology
Verified
Journal Article
Closed access
BBBrooke C Braman
Brooke C Braman
MCMartha A Cady
Martha A Cady
AMAllison A Merz-Herrala
Allison A Merz-Herrala
AWAlon Witztum
Alon Witztum
ZAZora Arum
Zora Arum
DRDavid R Raleigh
David R Raleigh
Meningiomas are among the few intracranial tumors that are more common in females than males. The majority of meningiomas express progesterone receptor (PR), and differences in exposure to progestogens are thought to contribute to sex-based disparity in meningioma. Previous epidemiological and clinical data have demonstrated that multiple progestins, such as cyproterone acetate (CPA), are linked to meningioma. More recently, international epidemiological studies have found a significantly increased risk of meningioma with depot medroxyprogesterone acetate (DMPA), a widely used injectable contraceptive sold under the trade name Depo-Provera. Although the absolute risk of meningioma remains small, exposure to DMPA increases the risk of meningioma by 1.5- to 5.5-fold. DMPA-associated meningiomas are clinically significant, as the risk of craniotomy for tumor resection, not just the risk of tumor diagnosis, is elevated after DMPA exposure. These data suggest that DMPA should be avoided in individuals with a history of meningioma when alternatives are available. The risk of meningioma should be discussed with patients during DMPA counseling, and the utility of screening patients with prolonged DMPA exposure for meningiomas should be investigated. Further work is needed to elucidate the mechanisms of PR signaling in meningioma and to understand the complex interplay of tumor genomics, hormone exposure and signaling, and social and structural drivers of health that may contribute to disparities in meningioma.

17 June 2026
Verified
Other
Open access
ACAbrar Choudhury
Abrar Choudhury
MCMartha A. Cady
Martha A. Cady
CLCalixto-Hope G. Lucas
Calixto-Hope G. Lucas
HNHINDA NAJEM
HINDA NAJEM
JPJoanna J. Phillips
Joanna J. Phillips
DRDavid R. Raleigh
David R. Raleigh
Supplementary Fig. 13. Analysis of human and mouse cell types from single-cell RNA sequencing of meningioma xenografts. A, Feature plots showing differentially expressed genes across UMAP clusters from CH-157MN meningioma xenograft human cells analyzed using single-cell RNA sequencing. See also Supplementary Table 5. B, Meningioma xenograft human single-cell cluster changes across experimental conditions and biological replicates. Student’s t-tests. C, Single-cell RNA sequencing UMAP of 34,902 meningioma xenograft mouse cell transcriptomes showing microenvironment cell types. D, Feature plots showing differentially expressed genes across UMAP clusters from meningioma xenograft mouse cells analyzed using single-cell RNA sequencing. E, Meningioma xenograft mouse single-cell cluster changes across experimental conditions and biological replicates. See also Supplementary Table 6. Student’s t tests.

17 June 2026
Verified
Other
Open access
PDF file
ACAbrar Choudhury
Abrar Choudhury
MCMartha A. Cady
Martha A. Cady
CLCalixto-Hope G. Lucas
Calixto-Hope G. Lucas
HNHINDA NAJEM
HINDA NAJEM
JPJoanna J. Phillips
Joanna J. Phillips
DRDavid R. Raleigh
David R. Raleigh
Supplementary Fig. 1. Single-cell RNA sequencing of human meningiomas with loss of chromosome 22q. A, Single-cell counts across UMAP clusters from human meningioma samples with loss of chromosome 22q analyzed using single-cell RNA sequencing. B, UMAP showing single-cell RNA sequencing of human meningioma samples shaded by sample of origin. C, Stacked bar plots showing the distribution of chromosome 22q loss (red) across single-cell RNA sequencing clusters from human meningioma samples. D, UMAP and stacked bar plot showing single-cell RNA sequencing cell cycle analysis across human meningioma samples. E-G, Heatmap and feature plots showing differentially expressed genes across UMAP clusters from human meningioma samples analyzed using single-cell RNA sequencing. Colors as in A. See also Supplementary Table 1. G, Feature plots showing expression of meningioma (SSTR2, PTGDS) or cancer stem-cell markers (NOTCH3, THY1) across UMAP clusters from human meningioma samples analyzed using single-cell RNA sequencing.

17 June 2026
Verified
Other
Open access
PDF file
ACAbrar Choudhury
Abrar Choudhury
MCMartha A. Cady
Martha A. Cady
CLCalixto-Hope G. Lucas
Calixto-Hope G. Lucas
HNHINDA NAJEM
HINDA NAJEM
JPJoanna J. Phillips
Joanna J. Phillips
DRDavid R. Raleigh
David R. Raleigh
Supplementary Fig. 5. WHO grade 2 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 expression is primarily restricted to the perivascular niche and colocalizes with mural cells in meningiomas with WHO grade 2 histology. SF numbers indicate individual meningiomas. WHO grade defined using histological criteria. Representative of n=10 WHO grade 2 meningiomas. Scale bars, 10µm.

17 June 2026
Verified
Other
Open access
PDF file
ACAbrar Choudhury
Abrar Choudhury
MCMartha A. Cady
Martha A. Cady
CLCalixto-Hope G. Lucas
Calixto-Hope G. Lucas
HNHINDA NAJEM
HINDA NAJEM
JPJoanna J. Phillips
Joanna J. Phillips
DRDavid R. Raleigh
David R. Raleigh
Supplementary Fig. 2. Single-cell RNA sequencing of dog meningiomas. A, Single-cell counts across UMAP clusters from dog meningioma samples analyzed using single-cell RNA sequencing. B, UMAP showing single-cell RNA sequencing of dog meningioma samples shaded by sample of origin. C, UMAP showing single-cell RNA sequencing cell cycle analysis across dog meningioma samples. D-E, Heatmapt and feature plots showing differentially expressed genes across UMAP clusters from dog meningioma samples analyzed using single-cell RNA sequencing. Colors as in A. F, Magnetic resonance imaging (MRI, left) or H&E images (right) of spontaneous dog meningiomas. Scale bars, 100µm. See also Supplementary Table 2.